Clinical

During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?

Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.

Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.

A review showed lifestyle intervention was linked to a 24% reduction in type 2 diabetes (T2D) incidence among women with prior gestational diabetes, compared with standard of care.

Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

The panel shares insights into the evolution of treatment strategies for patients with diabetes.

A panel of experts discuss considerations in insurance coverage for the treatment of patients with diabetes.

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).

Inhaler technique informs health care outcomes in COPD management and should be a primary focus in patient education priorities.

Treatment pathways, including escalation and de-escalation of therapy, for patients with COPD are explored by a panel of medical experts.

Patient advocate Paige Nues elaborates on the patient journey associated with a Rett syndrome diagnosis.

Paige Nues, from the International Rett Syndrome Foundation, provides insights on the diagnostic journey for patients with Rett syndrome.

Drs Weaver and Chitre discuss aligning key considerations for payers and goals of therapy for patients in the treatment of MDD.

Drs Weaver and Chitre share strategies to support MDD treatment adherence across their patient populations.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) includes researchon early interventions and possible health policy solutions.

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content.

This year’s most-popular content on psoriasis include research regarding disparities and socioeconomic factors that impact psoriasis treatment and an interview on shared decision making.

The relationship between aging and molecular profiles in myelodysplastic syndromes (MDS) is not well understood, but the findings suggest that different genetic alterations have distinct prognostic implications in different age groups.

The biomarker potential of Charcot-Leyden crystals in nasal tissue was investigated over 2 years in 110 patients with diagnosed chronic rhinosinusitis with nasal polyps (CRSwNP).

In 2022, the most-read articles published in Evidence-Based Oncology™ included the latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses emerging tools to use to identify patients with multiple myeloma for de-escalating treatment.

The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.

Bruce Sherman, MD, FCCP, FACOEM, underlines the impact of health inequities for patients diagnosed with psoriasis.

Maria Lopes, MD, MS, provides an overview of the PASI scoring system.

Amy McMichael, MD, discusses the impact of psoriasis on a patient’s quality of life.

Ryan Haumschild, PharmD, MS, MBA, leads a panel discussion highlighting the current prevalence of psoriasis.